Search DIAN Tissue Requests
Eain Murphy (David Butler, Co-Invesitigator)
Alzheimer’s Disease associated pathology induced by neurotropic viral infection.
03/03/2023
pending review
DIAN- T2303
Establish biomarkers and activity of SU110 and SU134 in iPSC-derived models of familial AD.
Do herpesvirus infections of neurons and glial cells produce neurodegenerative changes similar to those seen in Alzheimer’s Disease?
Assess the efficacy of anti-tau intrabodies to lower AD pathology in familial iPSC derived neurons with APP V717I iPSC mutation
Cruchaga
Identification of mutation-specific networks: deep molecular profiling
02/13/2023
pending review
DIAN-T2302
Identification and Characterization of Cell-Specific Transposable Elements Implicated on Alzheimer Disease and Healthy Aging
To generate neuron and microglia specific ATAC-seq, CAGE-seq, DNA methylation and long-reads RNA-seq
Randall Bateman
DIAN-TU-001 Gantenerumab Open Label Extension Study
01/27/2023
approved
DIAN-T2301
The primary objective of the DIAN-TU-001 Gant OLE (3 years study duration) is to determine if continued treatment with Gant at a target dose of 1500 mg (subcutaneous administration, every 2 weeks) can result in continued or complete removal of brain amyloid plaque using cerebral amyloid imaging by PiB PET.
The key secondary objective of the OLE is to evaluate the efficacy of Gant in reducing disease progression and will be assessed for the following key secondary efficacy outcome measures, such as CSF and plasma biomarkers.
Nikolaos Robakis
Effects of PS1 FAD mutants on brain angiogenesis.
10/17/2022
not approved
DIAN-T2209
Examine whether VEGFR2 dimerization, VEGFR2/CTF1 peptide, VEGFR2 complexes, VE-cadherin angiogenic complexes and levels of VEGF ligand differ in human FAD brains compared to control brains.
Ralph A. Nixon
PSEN FAD mutation effects on autophagy-lysosomal pathway related gene regulation
09/12/2022
approved
DIAN-T2208
Transcriptomic analysis of PSEN1 FAD mutations
Transcriptomic analysis of PSEN2 FAD mutations
Henderson
Stanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC modelsfor AD and PD
09/02/2022
approved
DIAN-T2207
AD/ADRD phenotypic characterization of iPSC neurons and microglia. Aim 2.1: We will differentiate and characterize cell lines into cortical neurons and microglia using established and validated protocols. Aim 2.2: We will characterize cell cultures and media supernatant for established AD biomarkers, including total tau, phosphorylated tau (Thr181), A1-40, and A1-42, neurofilament light (NfL), alpha-synuclein, cytokines and chemokines, immune profiling with CYTOF, proteomics, and comparative analyses to cerebrospinal fluid (CSF) biomarkers from the same donor.
Pharma partner
Comprehensive analyses of the soluble microtubule binding region (MTBR) in Alzheimer disease progression
08/17/2022
approved
DIAN-T2206
To test the performance of a pharma partner's antibody to identify unique soluble tau MTBR epitopes
Tammie Benzinger
Quantification of Neuroinflammation in Autosomal Dominant Alzheimer's Disease Using Small-block Brain Specimen imaged by Diffusion Basis Spectrum Imaging (DBSI)
08/16/2022
withdrawn
DIAN-T2205
to assess the value of DBSI for the study of ADAD by comparing post-mortem MRI signals with histologic data
Patrick Oeckl
Investigation of plasma Beta-Synuclein levels in asymptomatic and symptomatic autosomal dominant Alzheimer´s disease
06/20/2022
approved
DIAN-T2204
To investigate if blood levels of the synaptic marker Beta-Synuclein are already elevated in asymptomatic ADAD
To estimate a time course of blood Beta-Synuclein changes in ADAD based on EYO and comparison with other blood/CSF biomarkers
Relationship of blood Beta-Synuclein levels in ADAD with other fluid and imaging biomarkers, brain atrophy and cognitive impairment
Antonio Boza Serrano
Galectin-3 as a prognostic biomarker to monitor Autosomal dominant Alzheimer's Disease's progression
04/27/2022
not approved
DIAN-T2202
We aim to evaluate if gal3 levels are elevated in ADAD and if they might track the progression of AD pathology.
We want to compare the levels of gal3 with the levels of the classic biomarkers (amyloid-beta 42, total tau, p-tau (181, 217, etc), neurofilaments, precuneus SURV and PIB-Pet) as well as with global cognitive test (MMSE) and clinical measures (CDR total and SB) scores from the DIAN-obs